Publicado
Effect of Myrtenol-solid lipid nanoparticles on dexamethasone-induced hyperglycemia in rats
Efecto de las nanopartículas lipídicas sólidas de mirtenol sobre la hiperglucemia inducida por dexametasona en ratas
Efeito de nanopartículas lipídicas sólidas de mirtenol na hiperglicemia induzida por dexametasona em ratos
DOI:
https://doi.org/10.15446/rcciquifa.v55n3.127210Palabras clave:
Hyperglycemia, Myrtenol, Metformin, Wistar rats, steroid induce insulin resistance, solid lipid nanoparticles (en)Hiperglucemia, Myrtenol, Metformina, Ratas Wistar, Resistencia a la insulina inducida por esteroides, Nanopartículas lipídicas sólidas (es)
Hiperglicemia, Myrtenol, Metformina, Ratos Wistar, Resistência à insulina induzida por esteroides, Nanopartículas lipídicas sólidas (pt)
Descargas
Objective: To evaluate the hypoglycemic effect of myrtenol-solid lipid nanoparticles (Myrtenol-SLN) in dexamethasone-induced hyperglycemic rats. Methods: Thirty adult male Wistar rats were divided into five groups: normal control, normal treated with Myrtenol-SLN, hyperglycemic control, metformin-treated, and Myrtenol-SLN-treated groups. Hyperglycemia was induced by intraperitoneal dexamethasone (1 mg/kg) for 8 days. Treatments were administered orally for 10 days. Blood glucose levels were measured daily using a glucometer. Results: Myrtenol-SLN treatment significantly reduced blood glucose levels by day 5 and showed a highly significant reduction by day 10 compared with baseline values. The hypoglycemic effect of Myrtenol-SLN was comparable to metformin, with no significant differences observed between the two treatment groups during the study period. No adverse effects were detected throughout the experiment. Conclusions: Myrtenol-SLN demonstrated a significant hypoglycemic effect in dexamethasone-induced hyperglycemic rats and may represent a promising natural therapeutic approach for hyperglycemia management.
Objetivo: Evaluar el efecto hipoglucemiante de las nanopartículas lipídicas sólidas de mirtenol (Myrtenol-SLN) en ratas hiperglucémicas inducidas por dexametasona. Métodos: Treinta ratas Wistar macho adultas se dividieron en cinco grupos: control normal, control normal tratado con Myrtenol-SLN, control hiperglucémico, grupo tratado con metformina y grupo tratado con Myrtenol-SLN. La hiperglucemia se indujo mediante la administración intraperitoneal de dexametasona (1 mg/kg) durante 8 días. Los tratamientos se administraron por vía oral durante 10 días. Los niveles de glucosa en sangre se midieron diariamente con un glucómetro. Resultados: El tratamiento con Myrtenol-SLN redujo significativamente los niveles de glucosa en sangre al quinto día y mostró una reducción altamente significativa al décimo día en comparación con los valores basales. El efecto hipoglucemiante de Myrtenol-SLN fue comparable al de la metformina, sin observarse diferencias significativas entre los dos grupos de tratamiento durante el periodo de estudio. No se detectaron efectos adversos a lo largo del experimento. Conclusiones: Myrtenol-SLN demostró un efecto hipoglucemiante significativo en ratas hiperglucémicas inducidas por dexametasona y podría representar una prometedora alternativa terapéutica natural para el control de la hiperglucemia.
Objetivo: Avaliar o efeito hipoglicêmico de nanopartículas lipídicas sólidas de mirtenol (Mirtenol-SLN) em ratos com hiperglicemia induzida por dexametasona. Métodos: Trinta ratos Wistar machos adultos foram divididos em cinco grupos: controle normal, controle normal tratado com Myrtenol-SLN, controle hiperglicêmico, tratado com metformina e tratado com Myrtenol-SLN. A hiperglicemia foi induzida por dexametasona intraperitoneal (1 mg/kg) durante 8 dias. Os tratamentos foram administrados por via oral durante 10 dias. Os níveis de glicose no sangue foram medidos diariamente utilizando um glicosímetro. Resultados: O tratamento com Myrtenol-SLN reduziu significativamente os níveis de glicose no sangue no 5º dia e apresentou uma redução altamente significativa no 10º dia em comparação com os valores basais. O efeito hipoglicêmico do Myrtenol-SLN foi comparável ao da metformina, sem diferenças significativas observadas entre os dois grupos de tratamento durante o período do estudo. Nenhum efeito adverso foi detectado ao longo do experimento. Conclusões: O Myrtenol-SLN demonstrou um efeito hipoglicêmico significativo em ratos com hiperglicemia induzida por dexametasona e pode representar uma abordagem terapêutica natural promissora para o controle da hiperglicemia.
Referencias
1. M.J. Hossain, M. Al‐Mamun & M.R. Islam. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Science Reports, 7(3), e2004 (2024). https://doi.org/10.1002/hsr2.2004
2. E. Pardina, M. Tondo, J.C. Escolà-Gil, J. Rossell & J. Julve. Molecular mechanisms involved in hyperglycemia-induced cellular damage. In: M. Didac & A. Núria (editors). Chronic Complica-tions of Diabetes Mellitus: Current Outlook and Novel Pathophysiological Insights. Academic Press, 2024; pp. 25–38. https://doi.org/10.1016/b978-0-323-88426-6.00012-9
3. J.E. Kanter & K.E. Bornfeldt. Impact of Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascu-lar Biology, 36(6), 1049–1053 (2016). https://doi.org/10.1161/atvbaha.116.307302
4. Q. Huang, Y. Li, M. Yu, Z. Lv, F. Lu, N. Xu, Q. Zhang, J. Shen, J. Zhu & H. Jiang. Global burden and risk factors of type 2 diabetes mellitus from 1990 to 2021, with forecasts to 2050. Frontiers in Endocrinology (Lausanne), 16, 1538143 (2025). https://doi.org/10.3389/fendo.2025.1538143
5. J. Goldney, M.M. Barker, M. Thomas, T. Slater, M. Mickute, J.A. Sargeant, K. Khunti, M.J. Davies & F. Zaccardi. Age at onset of type 2 diabetes and prevalence of vascular disease and heart fail-ure: systematic review and dose-response meta-analysis. Journal of Diabetes and its Complica-tions, 38(10), 108849 (2024). https://doi.org/10.1016/j.jdiacomp.2024.108849
6. S.I. Taylor, Z.S. Yazdi & A.L. Beitelshees. Pharmacological treatment of hyperglycemia in type 2 diabetes. The Journal of Clinical Investigation, 131(2), e142243 (2021). https://doi.org/10.1172/jci142243
7. N. Shahzad, A.R. Alzahrani, I.A.A. Ibrahim, I. Shahid, I.M. Alanazi, A.H. Falemban, M.T. Imam, N. Mohsin, M.F.N. Azlina & P. Arulselvan. Therapeutic strategy of biological macromolecules based natural bioactive compounds of diabetes mellitus and future perspectives: A systematic review [Retracted]. Heliyon, 10, e24207 (2024). https://doi.org/10.1016/j.heliyon.2024.e24207
8. P.A. Barbhuiya & M.P. Pathak. Myrtenol: A promising terpene with potent pharmacological properties. Pharmacological Research - Natural Products, 4, 100067 (2024). https://doi.org/10.1016/ j.prenap.2024.100067
9. D. Cvitković, I. Škarica, V. Dragović-Uzelac & S. Balbino. Supercritical CO2 extraction of fatty acids, phytosterols, and volatiles from myrtle (Myrtus communis L.) fruit. Molecules, 29(8), 1755 (2024). https://doi.org/10.3390/molecules29081755
10. G. Bozsik, B.P. Molnár, K. Hegedüs, T. Soós, S. Schulz, A. Tröger, W. Francke & G. Szőcs. (−)‐myrtenol and (−)‐α‐pinene: Aggregation pheromone components of the cypress bark beetle Phloeosinus aubei. Journal of Applied Entomology, 148(4), 351–363 (2024). https://doi.org/10.1111/jen.13233
11. J. Yang, S. Ni, A. Wang, K. Wang, J. Deng, Z. Li, Y. Cai, Y. Chen, G. Chen & D. Lin. Myrtenol promotes skin flap survival by inhibiting apoptosis and promoting autophagy via the MEK/ERK pathway. Archives of Biochemistry and Biophysics, 763, 110230 (2025). https://doi.org/10.1016/ j.abb.2024.110230
12. M.A. Rajizadeh, M. Ghasemi, M.A. Bejeshk, M. Akhbari, S. Saberi, F. Bagheri & S. Amiresmaili. Evaluation of the modifying impact of myrtenol on intrahepatic cholestasis and extrahepatic cholestasis in male rats: role of oxidative stress and inflammation. Advances in Traditional Medi-cine, 26, 433–447 (2025). https://doi.org/10.1007/s13596-025-00857-3
13. M.S. Solgi, M. Bahrami, M. Salehi, N. Saeidi, A. Almasi-Hashiani & S.A. Latifi. Myrtle syrup improves proteinuria in type 2 diabetic patients: A randomized double-blinded placebo-controlled clinical trial. Galen Medical Journal, 14, e3712 (2025). https://doi.org/10.31661/gmj.v14i.3712
14. H.A. Mohammed, R.A. Khan, V. Singh, M. Yusuf, N. Akhtar, G.M. Sulaiman, S. Albukhaty, A.A.H. Abdellatif, M. Khan, S.A.A. Mohammed & AM. Al-Subaiyel. Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development. Nanotechnology Reviews, 12(1), 20220517 (2023). https://doi.org/10.1515/ntrev-2022-0517
15. C. Viegas, A.B. Patrício, J.M. Prata, A. Nadhman, P.K. Chintamaneni & P. Fonte. Solid lipid na-noparticles vs. nanostructured lipid carriers: A comparative review. Pharmaceutics, 15(6), 1593 (2023). https://doi.org/10.3390/pharmaceutics15061593
16. A.K. Singh, M. Kumar & P.K. Upadhyay. Methods for the encapsulation of hydrophilic drugs in lipid-based nanocarriers, solid lipid nanoparticles, and nanostructured lipid carriers: A short review and perspective. Current Nanomedicine, 15(4), 448–458 (2025). https://doi.org/10.2174/ 0124681873316337240515080103
17. A.K. Chettupalli, A. Unnisa, H. Peddapalli, R.K. Jadi, K. Anusha & P.R. Amarachinta. Develop-ment and evaluation of empagliflozin-loaded solid lipid nanoparticles: Pharmacokinetics and pharmacodynamics for oral delivery. Intelligent Pharmacy, 3(3), 193–206 (2025). https://doi.org/10.1016/ j.ipha.2024.12.004
18. L.S. Singh. Developing nanocarrier-based formulations of antidiabetic drugs derived from me-dicinal plants: A systemic review. Pharmacological Research - Natural Products, 2, 100004 (2024). https://doi.org/10.1016/j.prenap.2023.100004
19. F.J. Alyasiri, M. Ghobeh & M.H. Tabrizi. Preparation and characterization of allicin-loaded solid lipid nanoparticles surface-functionalized with folic acid-bonded chitosan: In vitro anti-cancer and antioxidant activities. Frontiers in Bioscience (Landmark Ed.), 28(7), 135 (2023). https://doi.org/ 10.31083/j.fbl2807135
20. M.L. Bondi, G. Fontana, B. Carlisi & G. Giammona. Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Delivery, 10, 245–250 (2003). https://doi.org/10.1080/drd_10_4_245
21. M.T. Wego, S.L.P. Kamani, D. Miaffo, M.L. Nchouwet, A. Kamanyi & S.L.W. Ngnokam. Protec-tive effects of aqueous extract of Baillonella toxisperma Stem Bark on dexamethasone-induced insulin resistance in rats. Advances in Pharmacological and Pharmaceutical Sciences, 2019, 8075163 (2019). https://doi.org/10.1155/2019/8075163
22. P. Mahendran & C.S. Devi. Effect of Garcinia cambogia extract on lipids and lipoprotein compo-sition in dexamethasone administered rats. Indian Journal of Physiology and Pharmacology, 45(3), 345–350 (2001). URL: https://ijpp.com/IJPP%20archives/2001_45_3/345-350.pdf
23. M. Al Za’abi, B.H. Ali, Y. Al Suleimani, S.A. Adham, H. Ali, P. Manoj, M. Ashique & A. Nem-mar. The effect of metformin in diabetic and non-diabetic rats with experimentally-induced chronic kidney disease. Biomolecules, 11(6), 814 (2021). https://doi.org/10.3390/biom11060814
24. S. Tas, B. Tas, N. Bassalat & N. Jaradat. In-vivo, hypoglycemic, hypolipidemic and oxidative stress inhibitory activities of Myrtus communis L. fruits hydroalcoholic extract in normoglyce-mic and streptozotocin-induced diabetic rats. Biomedical Research, 29(13), 2727–2734 (2018). https://doi.org/10.4066/biomedicalresearch.29-18-708
25. E.K. Batista, L.M.A. de Lima, D.A. Gomes, D.C. Crans, W.E. Silva, M.F. Belian & E.C. Lira. Dex-amethasone-induced insulin resistance attenuation by oral sulfur–oxidovanadium (IV) com-plex treatment in mice. Pharmaceuticals, 17(6), 760 (2024). https://doi.org/10.3390/ph17060760
26. M. Kutyła, M. Pięt, M. Stankevič, A. Junka, M. Brożyna, B. Dudek, R. Paduch & M. Trytek. Oxi-dation of myrtenol to myrtenal epoxide in a porphyrin-based photocatalytic system – A novel terpene alcohol derivative with antimicrobial and anticancer properties. Bioorganic Chemistry, 154, 108047 (2025). https://doi.org/10.1016/j.bioorg.2024.108047
27. M. Ohira, N. Kawagoe, C. Kameyama, Y. Kondou, M. Igarashi & H. Ueshiba. Association of serum cortisol with insulin secretion and plasma aldosterone with insulin resistance in untreat-ed type 2 diabetes: a cross-sectional study. Diabetology & Metabolic Syndrome, 17, 144 (2025). https://doi.org/10.1186/s13098-025-01706-8
28. R. Chalotra, T. Gupta, S. Chib, M. Amanat, P. Kumar & R. Singh. Treatment of diabetic compli-cations: do flavonoids holds the keys? Critical Reviews in Food Science and Nutrition, 64(30), 11091–11112 (2024). https://doi.org/10.1080/10408398.2023.2232868
29. G. Feriotto, F. Tagliati, V. Costa, M. Monesi, C. Tabolacci, S. Beninati & C. Mischiati. -Pinene, a main component of Pinus essential oils, enhances the expression of insulin-sensitive glucose transporter type 4 in murine skeletal muscle cells. International Journal of Molecular Sciences, 25(2), 1252 (2024). https://doi.org/10.3390/ijms25021252
30. G.R. Gandhi, V.E. Hillary, P.J. Antony, L.L.D. Zhong, D. Yogesh, N.M. Krishnakumar, S.A. Ceasar & R.-Y. Gan. A systematic review on anti-diabetic plant essential oil compounds: Die-tary sources, effects, molecular mechanisms, and safety. Critical Reviews in Food Science and Nu-trition, 64(19), 6526–6545 (2024). https://doi.org/10.1080/10408398.2023.2170320
31. S.K. Afshar, F. Rostamzadeh, M.R. Bigdeli & F.M. Moghadam. Myrtenol-loaded fatty acid nanocarriers protect rat brains against ischemia-reperfusion injury: Antioxidant and anti-inflammatory effects. Chemical Biology & Drug Design, 104(3), e14633 (2024). https://doi.org/10.1111/cbdd.14633
32. H.N. Mrabti, I. Jaouadi, I. Zeouk, R. Ghchime, N. El Menyiy, N. El Omari, A. Balahbib, S.H. Al-Mijalli, E.M. Abdallah, M. El-Shazly, G. Zengin & A. Bouyahya. Biological and pharmacological properties of myrtenol: A review. Current Pharmaceutical Design, 29(6), 407–414 (2023). https://doi.org/10.2174/1381612829666221222121041
Dimensions
PlumX
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2026 Revista Colombiana de Ciencias Químico-Farmacéuticas
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.
Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13
